Understand the source comparison
Peptides for NASH Liver: Mechanism Comparison
BPC-157 NF-κB inhibition, angiogenesis Reduces stellate cell activation and fibrosis 250–500 mcg SC daily Preclinical (animal models) Thymosin Beta-4 Actin polymerization, anti-apoptotic Promotes hepatocyte regeneration 2–5 mg SC twice weekly Preclinical + Pha
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- NF-κB inhibition, angiogenesis
- Reduces stellate cell activation and fibrosis
- 250–500 mcg SC daily
- Preclinical (animal models)
- Thymosin Beta-4
- Actin polymerization, anti-apoptotic
- Promotes hepatocyte regeneration
- 2–5 mg SC twice weekly
- Preclinical + Phase 2 trials
- Semaglutide (GLP-1)
- GLP-1 receptor agonist
- Improves insulin sensitivity, reduces lipogenesis
- 0.25–2.4 mg SC weekly
- Phase 3 clinical trials (NASH resolution)
- Ipamorelin + CJC-1295
- GH secretagogue
- Enhances lipolysis, protein synthesis
- 200–300 mcg SC daily
- Preclinical (indirect metabolic benefit)
- Tirzepatide (GIP/GLP-1)
- Dual incretin agonist
- Insulin sensitivity + weight reduction
- 2.5–15 mg SC weekly
- Phase 3 trials (metabolic dysfunction)